Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  3SBio Inc. (ADR)    YFK

No quotes available
-- EUR   0.00%
03/04 3SBIO : Bought CNY3.9bn Shares in CPGJ
03/04 3SBIO : adds stake in CP Guojian Pharma at Rmb3.9bn
02/23 3SBIO : Wins Financing for Further Equity Investment
 SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CNY)
Sales 2016 2 506 M
EBIT 2016 916 M
Net income 2016 824 M
Debt 2016 448 M
Yield 2016 0,19%
Sales 2017 3 121 M
EBIT 2017 1 164 M
Net income 2017 1 055 M
Finance 2017 463 M
Yield 2017 -
P/E ratio 2016 24,52
P/E ratio 2017 18,83
EV / Sales 2016 8,08x
EV / Sales 2017 6,20x
Capitalization 19 810 M
More Financials
Company
3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products.It is used in the field of medicine particularly in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.The company... 
Sector
Pharmaceuticals
Calendar
05/11Earnings Release
More about the company
Surperformance© ratings of 3SBio Inc. (ADR)
Trading Rating : Investor Rating :
More Ratings
Latest news on 3SBIO INC. (ADR)
03/17 3SBIO : PEG-irinotecan Wins IND Approval From China FDA
03/04 3SBIO : Bought CNY3.9bn Shares in CPGJ
03/04 3SBIO : adds stake in CP Guojian Pharma at Rmb3.9bn
02/23 3SBIO : Wins Financing for Further Equity Investment
02/23 3SBIO : inks Rmb2.2bn term loan facility
01/27 3SBIO : to add stake in CP Guojian Pharmaceutical
01/20 3SBIO : to add stake in CP Guojian
01/05DJChinese Drugmaker Plans up to $3 Billion Hong Kong IPO
More news
Sector news : Biopharmaceuticals
11:28pDJAbbott Agreed to Buy St. Jude in $25 Billion Deal--6th Update
11:10p Facebook and St. Jude Medical surge, GNC and AbbVie skid
11:01pDJDrugmakers Place Big Bets on Cancer Medicines
More sector news : Biopharmaceuticals
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions